December 1, 2015
Savy Akers’ production facility in China fully operational
Savy Akers’ 10,000 square foot production facility in Haikou National Hi-Tech Industrial Zone, Hainan province, is now fully operational.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Asia
December 1, 2015
Tuberculosis funding gap threatens elimination goals
Funding for tuberculosis research fell $1.3 billion short of global targets last year, threatening worldwide goals to eliminate the disease between 2030 and 2035, researchers said on Monday.
November 30, 2015
Cipla launching low-dose Efavirenz 400 mg HIV infection therapy
Cipla launching low-dose Efavirenz 400 mg HIV infection therapy
November 30, 2015
Teva and Takeda are forming a new joint venture to operate generics in Japan
Teva and Takeda are forming a new joint venture to operate in Japan
November 30, 2015
India progresses towards polio-free world
“Ours will be the last generation to see the horror of children paralyzed or killed by polio. I am sure,” said Pr Jacob John, Former Christian Medical College, Vellore, Tamil Nadu, India.
“Maybe we will remember 2015 as the year we took the final step to eradicate this disease forever.”
November 27, 2015
(Edited) RPG Life Science calms down investors. Says media writings are premature
RPG Life Science Limited has said that the media reports which said that “RPG Life Plans Skincare Foray, May Roll Out Biz Next Month” came out premature.
November 26, 2015
GSK in China – escaping the shadow of a scandal
GlaxoSmithKline Plc has cut 40 percent of its sales reps in China and axed some units as it eyes a return to growth in 2016, after sales plunged during a bribery scandal that landed it with a record $490 million fine in 2014.
November 26, 2015
FDA may withhold approval of Dr. Reddy’s new applications or supplements listing
The FDA said that, until Dr. Reddy’s complete all corrections and FDA confirms its compliance with CGMP, it may withhold approval of any new applications or supplements listing Dr. Reddy as a drug product or API manufacturer.
November 26, 2015
Teva to receive global development and commercial rights to Hemtares’ novel CGRP antagonists
Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Sosei Group’s subsidiary Heptares, for the treatment of migraine.
November 24, 2015
Lupin gets a go-ahead to market Blisovi – generic version Warner Chilcott’s Loestrin tablets – in U.S.
US FDA has given Lupin a go to market Blisovi Fe 1/20 Tablets and Blisovi 1.5/30 Tablets market generic versions of Warner Chilcott’s Loestrin Fe 1/20 Tablets and Loestrin Fe 1.5/30 Tablets.